Also trades as: MAYNF (OTC) · $vol 0M
MYX.AX ASX
Mayne Pharma Group Limited
1W: +1.4%
1M: -8.4%
3M: -1.0%
YTD: +0.3%
1Y: -45.1%
3Y: -19.0%
5Y: -52.3%
A$2.82 ($1.96)
-0.03 (-1.05%)
Weekly Expected Move ±5.6%
A$3
A$3
A$3
A$3
A$3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$384M
-6.0% ▼
5Y CAGR: -0.9%
Gross Profit
$192M
-22.3% ▼
5Y CAGR: +8.6%
Operating Income
-$34M
-45.3% ▼
Net Income
$24M
+126.1% ▲
EPS (Diluted)
$0.21
+118.4% ▲
EBITDA
$29M
-30.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $157M | $184M | $388M | $408M | $384M |
| YoY Growth | -60.8% | +16.8% | +111.4% | +5.1% | -6.0% |
| Cost of Revenue | $133M | $157M | $170M | $161M | $191M |
| Gross Profit | $24M | $27M | $219M | $247M | $192M |
| Gross Margin | 15.1% | 14.6% | 56.3% | 60.6% | 50.1% |
| R&D Expenses | $12M | $16M | $20M | $19M | $21M |
| SG&A Expenses | $133M | $184M | $217M | $251M | $206M |
| Operating Expenses | $146M | $213M | $358M | $271M | $226M |
| Operating Income | -$122M | -$186M | -$139M | -$24M | -$34M |
| Operating Margin | -77.6% | -101.6% | -35.8% | -5.8% | -8.9% |
| Interest Expense | $12M | $10M | $5M | $5M | $5M |
| Income Before Tax | -$146M | -$270M | -$190M | -$83M | $36M |
| Tax Expense | $75M | $48M | -$21M | $7M | $5M |
| Net Income | -$281M | $117M | -$174M | -$94M | $24M |
| Net Margin | -179.0% | 63.9% | -44.9% | -23.0% | 6.4% |
| EPS (Diluted) | $-3.46 | $-3.89 | $-2.19 | $-1.14 | $0.21 |
| EBITDA | -$79M | -$194M | -$117M | $42M | $29M |
| Shares Outstanding | 81M | 81M | 80M | 79M | 106M |